Athena Athena

X
[{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmAbcine Expands Partnership with Samsung Biologics for PMC-403","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Biologics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Samsung will provide CDO services from cell line development, process development, cGMP clinical manufacturing to IND filing support for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular disorders.

            Lead Product(s): PMC-403

            Therapeutic Area: Ophthalmology Product Name: PMC-403

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: PharmAbcine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership September 21, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY